A Study of Filgotinib in Korean Participants With Rheumatoid Arthritis
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-03-19
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the percentage of participants achieving an American College of Rheumatology (ACR) 20 percent (%) Improvement (ACR20) response at Week 12 of the administration of the investigational product.